Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volenrelaxin phase 2 study in adults with chronic kidney disease
jRCT2051240155Phase 2Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of volenrelaxin in chronic kidney disease (CKD) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percent change from baseline of urine albumin-creatinine ratio. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
volenrelaxin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2051240155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240155.